查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675376

微小残留疾病检测市场按技术（流式细胞仪、聚合酶炼式反应、下一代定序等）、应用、最终用户和地区划分，2025 年至 2033 年

Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球微小残留疾病 ( IMARC Group ) 检测市场规模达到 23 亿美元。医疗保健产业的显着成长、广泛的研究和开发 (R&D) 活动和快速的技术进步是推动市场发展的一些关键因素。

微小残留疾病（MRD）检测是一种医学检测，用于检测和监测患者接受癌症治疗后可能残留在体内的少量癌细胞。它被广泛用于检测多种不同类型的癌症，例如白血病、淋巴瘤、多发性骨髓瘤和一些实体肿瘤。 MRD 检测使用高度敏感的方法，包括流式细胞仪、聚合酶链反应 (PCR) 和次世代定序 (NGS)。它是监测癌症患者并帮助医生做出更明智治疗决策的重要医学测试。 MRD 检测有助于早期发现疾病復发，提供更准确的治疗反应评估，并透过识别患者、改善患者结果和加强客製化治疗计划来指导个人化治疗计划。

微小残留疾病 (MRD) 检测市场趋势：

全球癌症发生率的上升是推动市场成长的关键因素之一。 MRD 检测是一种高度敏感的技术，广泛用于检测残留癌细胞，有助于早期发现疾病復发并有助于指导个人化治疗计划。与此一致，MRD 测试被广泛采用作为始于造血组织或免疫系统细胞的血液系统癌症的诊断和监测工具，有利于市场的成长。此外，消费者对允许客製化治疗计划和监测的个人化医疗的偏好转变也是另一个促进成长的因素。除此之外，人工智慧 (AI) 与 MRD 测试的结合有助于识别模式、预测復发的可能性、提高诊断的准确性和有效性，并帮助临床医生就患者护理做出更明智的决策，从而为市场成长提供了动力。此外，越来越多地采用NGS技术来确定脱氧核糖核酸（DNA）或核糖核酸（RNA）的序列以研究与疾病相关的遗传变异，为市场创造了积极的前景。此外，人们越来越意识到识别体内是否存在可能导致癌症的致癌物质的重要性，这推动了市场的成长。其他因素，包括医疗保健行业的显着增长、广泛的研究和开发 (R&D) 活动以及对 MRD 测试项目领域的投资增加，预计将推动市场成长。

本报告回答的关键问题：

  • 全球微小残留疾病（MRD）检测市场迄今表现如何，未来几年将如何表现？
  • 全球微小残留疾病 (MRD) 检测市场的驱动因素、限制因素和机会有哪些？
  • 每个驱动因素、限制因素和机会对全球微小残留疾病 (MRD) 检测市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家拥有最具吸引力的微小残留疾病 (MRD) 检测市场？
  • 基于科技的市场分化是怎样的？
  • 微小残留疾病（MRD）检测市场中哪种技术最具吸引力？
  • 根据应用，市场区隔是怎样的？
  • 微小残留疾病（MRD）检测市场中最具吸引力的应用是什么？
  • 根据最终用户，市场分布如何？
  • 微小残留疾病（MRD）检测市场中最具吸引力的最终用户是谁？
  • 全球微小残留疾病（MRD）检测市场的竞争结构如何？
  • 全球微小残留疾病 (MRD) 检测市场的关键参与者/公司有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球微小残留疾病 (MRD) 检测市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第六章：市场区隔：依技术

  • 流式细胞仪
  • 聚合酶炼式反应（PCR）
  • 下一代定序（NGS）
  • 其他的

第七章：市场区隔：依应用

  • 血液系统恶性肿瘤
    • 关键部分
      • 白血病
      • 淋巴瘤
  • 实体肿瘤

第 8 章：市场区隔：依最终用户

  • 医院和专科诊所
  • 诊断实验室
  • 学术及研究机构
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 10 章：驱动因素、限制因素与机会

  • 概述
  • 驱动程式
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Adaptive Biotechnologies Corporation
    • Arup Laboratories Inc.
    • Bio-Rad Laboratories Inc.
    • Guardant Health
    • Invivoscribe Inc.
    • Natera Inc.
    • NeoGenomics Laboratories Inc.
    • Sysmex Corporation
Product Code: SR112025A7248

The global minimal residual disease (MRD) testing market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.7% during 2025-2033. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

Technology Insights:

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Others

Application Insights:

  • Hematological Malignancy
  • Leukemia
  • Lymphoma
  • Solid Tumors

End User Insights:

  • Hospitals and Speciality Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:

  • How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
  • What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
  • What are the key regional markets?
  • Which countries represent the most attractive minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the minimal residual disease (MRD) testing market?
  • What is the competitive structure of the global minimal residual disease (MRD) testing market?
  • Who are the key players/companies in the global minimal residual disease (MRD) testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Minimal Residual Disease (MRD) Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Flow Cytometry
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymerase Chain Reaction (PCR)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Next Generation Sequencing (NGS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hematological Malignancy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Leukemia
      • 7.1.2.2 Lymphoma
    • 7.1.3 Market Forecast
  • 7.2 Solid Tumors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Speciality Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adaptive Biotechnologies Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Arup Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Bio-Rad Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Guardant Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Invivoscribe Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Natera Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 NeoGenomics Laboratories Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Sysmex Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
  • Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
  • Table 7: Global: Minimal Residual Disease Testing Market: Key Players